[go: up one dir, main page]

MX2013007335A - Formulaciones solidas de retardo basadas en dispersiones solidas. - Google Patents

Formulaciones solidas de retardo basadas en dispersiones solidas.

Info

Publication number
MX2013007335A
MX2013007335A MX2013007335A MX2013007335A MX2013007335A MX 2013007335 A MX2013007335 A MX 2013007335A MX 2013007335 A MX2013007335 A MX 2013007335A MX 2013007335 A MX2013007335 A MX 2013007335A MX 2013007335 A MX2013007335 A MX 2013007335A
Authority
MX
Mexico
Prior art keywords
solid
formulations based
dispersions
formulation
pharmaceutically acceptable
Prior art date
Application number
MX2013007335A
Other languages
English (en)
Other versions
MX341873B (es
Inventor
Bernd Liepold
Gunther Berndl
Ute Lander
Juergen Weis
Dietrich Granzow
Ulrich Westedt
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MX2013007335A publication Critical patent/MX2013007335A/es
Publication of MX341873B publication Critical patent/MX341873B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación que comprende un producto de dispersión sólida procesado en estado fundido, que comprende un agente activo, un polímero termoplástico de N-vinil-lactama farmacéuticamente aceptable, y un copolímero de injerto de alcohol polivinílico - polialquilenglicol, farmacéuticamente aceptable. Un método de producción de dicha formulación.
MX2013007335A 2010-12-23 2011-12-22 Formulaciones solidas de retardo basadas en dispersiones solidas. MX341873B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10196936 2010-12-23
PCT/EP2011/073850 WO2012085236A1 (en) 2010-12-23 2011-12-22 Solid retard formulations based on solid dispersions

Publications (2)

Publication Number Publication Date
MX2013007335A true MX2013007335A (es) 2014-03-05
MX341873B MX341873B (es) 2016-09-06

Family

ID=44063216

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007335A MX341873B (es) 2010-12-23 2011-12-22 Formulaciones solidas de retardo basadas en dispersiones solidas.

Country Status (14)

Country Link
US (1) US10463739B2 (es)
EP (1) EP2654731B1 (es)
JP (1) JP5903686B2 (es)
CN (1) CN103260609B (es)
CA (1) CA2821659C (es)
DK (1) DK2654731T3 (es)
ES (1) ES2598235T3 (es)
MX (1) MX341873B (es)
PL (1) PL2654731T3 (es)
PT (1) PT2654731T (es)
RU (1) RU2013134339A (es)
SG (1) SG191316A1 (es)
WO (1) WO2012085236A1 (es)
ZA (1) ZA201304487B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114170B2 (en) * 2012-11-08 2015-08-25 Isp Investments Inc. Highly loaded amorphous efavirenz composition and process for preparing the same
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CN107920976A (zh) 2015-08-20 2018-04-17 荷兰联合利华有限公司 改善的内酰胺溶解度
BR112018003173B1 (pt) 2015-08-20 2021-12-14 Nilever Ip Holdings B.V. Lactama encapsulada, aditivo, composição e método de encapsulamento de uma lactama
CN107847416B (zh) * 2015-08-20 2021-07-20 荷兰联合利华有限公司 分散的内酰胺
US10888087B2 (en) 2015-08-20 2021-01-12 Conopco, Inc. Lactam solubility
US11077036B2 (en) 2015-08-20 2021-08-03 Conopco, Inc. Lactam solubility
US20190175589A1 (en) * 2017-11-09 2019-06-13 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
CN112263567B (zh) * 2020-10-19 2022-05-03 南京易亨制药有限公司 一种布洛芬缓释胶囊及制备方法
AU2022229953A1 (en) * 2021-03-04 2023-09-07 Reckitt Benckiser Health Limited Novel composition
US20240189239A1 (en) * 2021-04-01 2024-06-13 Merck Patent Gmbh Process for continuous hot melt granulation of low soluble pharmaceuticals

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1077430B (de) 1958-04-15 1960-03-10 Hoechst Ag Verfahren zur Herstellung von Pfropfpolymerisaten von Polyvinylestern
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3536530A1 (de) 1985-10-12 1987-04-23 Basf Ag Verwendung von pfropfcopolymerisaten aus polyalkylenoxiden und vinylacetat als vergrauungsinhibitoren beim waschen und nachbehandeln von synthesefasern enthaltendem textilgut
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE60028754T2 (de) 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
JP4284199B2 (ja) * 2004-01-26 2009-06-24 株式会社日立コミュニケーションテクノロジー 光クロスコネクト装置及び網管理装置
DE602006016127D1 (de) * 2005-07-05 2010-09-23 Abbott Gmbh & Co Kg Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
CA2641351C (en) * 2006-02-03 2014-05-06 Christian Meier Pharmaceutical compositions containing mixtures of polymers and active agents poorly soluble in water
EP1832281A1 (en) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
GB0607105D0 (en) 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
AR068916A1 (es) * 2007-10-19 2009-12-16 Abbott Gmbh & Co Kg Producto de dispersion solida que contiene un compuesto a base de n- aril urea
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
JP5654002B2 (ja) 2009-05-13 2015-01-14 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリエーテルに基づくコポリマーを微水溶性ポリマーと組み合わせて含む固体医薬調製物

Also Published As

Publication number Publication date
CA2821659A1 (en) 2012-06-28
PL2654731T3 (pl) 2017-01-31
DK2654731T3 (en) 2016-11-14
JP5903686B2 (ja) 2016-04-13
EP2654731B1 (en) 2016-07-27
US10463739B2 (en) 2019-11-05
EP2654731A1 (en) 2013-10-30
ZA201304487B (en) 2014-03-26
MX341873B (es) 2016-09-06
SG191316A1 (en) 2013-07-31
PT2654731T (pt) 2016-11-07
HK1189834A1 (en) 2014-06-20
WO2012085236A1 (en) 2012-06-28
RU2013134339A (ru) 2015-01-27
ES2598235T3 (es) 2017-01-26
US20140296336A1 (en) 2014-10-02
CA2821659C (en) 2019-05-14
JP2014500299A (ja) 2014-01-09
CN103260609A (zh) 2013-08-21
CN103260609B (zh) 2017-08-11

Similar Documents

Publication Publication Date Title
MX2013007335A (es) Formulaciones solidas de retardo basadas en dispersiones solidas.
CO7071123A2 (es) Formulaciones basadas en dispersiones solidas
CO6640208A2 (es) Composiciones solidas
HK1224208A1 (zh) 药物递送系统
WO2008100375A3 (en) Polymer-based films and drug delivery systems made therefrom
AU2011284474B9 (en) Ophthalmic device molds formed from water-soluble vinyl alcohol copolymer, ophthalmic devices molded therein, and related methods
WO2012174466A3 (en) Nanoscale particle formulations and methods
WO2010068356A3 (en) System and method for communicating over a network with a medical device
WO2013158814A8 (en) Immediate release, abuse deterrent pharmaceutical compositions
WO2012080383A3 (en) Personal care compositions including aqueous compositions of viscoelastic surfactants and hydrophobically modified polymers
EP4212146A3 (en) Core sheath drug delivery devices
AR086945A1 (es) Material polimerico para un recipiente aislante
BR112012010992A2 (pt) formulação de gel de polissacarídeo tendo distribuição de agente bioativo em estágios múltiplos
HK1208216A1 (en) Drug-conjugates, conjugation methods, and uses thereof
WO2011084620A3 (en) Particles for multiple agent delivery
WO2009036098A3 (en) Apparatus, systems and techniques for interfacing with an eye in laser surgery
WO2007135461A3 (en) Pharmaceutical compositions comprising implitapide and methods of using same
CL2008003092A1 (es) Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .
WO2011034883A3 (en) Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions
JP2011518842A5 (es)
WO2011034877A3 (en) Silicone deposition aid for personal care compositions
WO2014081581A3 (en) Highly loaded amorphous efavirenz composition and process for preparing the same
WO2015001087A3 (en) Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
WO2011156579A3 (en) Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE DEUTSCHLAND GMBH & CO. KG.

FG Grant or registration